MAIA Biotechnology, Inc. (MAIA) Stock Price

MAIAStock
$1.3312.50%52W
Market Cap$80.91M
P/E
PEG Ratio
Div yield
Beta0.26

MAIA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-56.97%
Price vs S&P 500 (4W)-0.78%
VGM Score44.63

MAIA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.11-$0.13-18.18%(-$0.02)
Q1 2026-$0.18-$0.14+22.22%(+$0.04)
Q4 2025-$0.13-$0.14-5.23%(-$0.01)
Q3 2025-$0.19-$0.27-42.11%(-$0.08)
Q2 2025-$0.25-$0.17+32.84%(+$0.08)

MAIA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
MAIAMAIA Biotechnology, Inc.
C$1.33
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About MAIA Biotechnology, Inc.

MAIA Biotechnology is a clinical-stage biopharmaceutical company developing THIO, an investigational drug candidate with dual anti-cancer mechanisms targeting telomeres and immune function. The lead program combines THIO with Regeneron's approved checkpoint inhibitor Libtayo (cemiplimab) to treat patients with advanced non-small cell lung cancer. The combination approach aims to enhance the immune system's ability to attack cancer cells.